Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: From animal studies to clinical trials

Magnesium Research

Volumn 11, Issue 2, 1998, Pages 133-140

  Serebruany, Victor L ^a,e   Atar, Dan ^b   Dalesandro, Margaret R ^c   O'Connor, Christopher M ^d   Gurbel, Paul A ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CENTOCOR INC   (United States)

^d DUKE UNIVERSITY   (United States)

^e NONE

Author keywords

Acute myocardial infarction; Animal model; Humans; Magnesium; Mechanisms; Myocardial ischemia reperfusion

Indexed keywords

MAGNESIUM;

ANIMAL; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; HEART INFARCTION; HEMOSTASIS; HUMAN; INFUSION; REPERFUSION INJURY; REVIEW;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HEMOSTASIS; HUMANS; INFUSIONS, PARENTERAL; MAGNESIUM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

EID: 0032088418     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Thel, M.C. & O'Connor, C.M. (1995): Magnesium in acute myocardial infarction. Coron. Artery Dis. 6, 831-837.
2. Durlach, J. & Rayssiguier, Y. (1993): Fatty acid profile, fibre content and high magnesium density of nuts may protect against risk of coronary heart disease events. Magnes. Res. 6, 191-192.
3. Herzog, W.R. & Serebruany, V.L. (1996): How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. Coron. Artery Dis. 7, 364-371.
4. Durlach, J., Durlach, V., Bac, P., Bara, M. & Guiet-Bara, A. (1994): Magnesium and therapeutics. Magnes. Res. 7, 313-328.
5. Atar, D., Serebruany, V., Poulton, J., Godard, J., Sneider, A. & Herzog, W. (1994): Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. 24, 603-611.
6. Vincent, R. (1996): Advances in the early diagnosis and management of acute myocardial infarction. J. Accident. Emerg. Med. 13, 74-79.
7. Durlach, J. (1967): Magnesium-deficiency thrombosis (letter). Lancet 1, 13821.
8. Hwang, D., Yen, C. & Nadler, J. (1992): Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am. J. Hypertens. 5, 700-706.
9. Herrman RG, Lacefield WB, Crwe VG (1970): Effect of ionic calcium and magnesium on human platelet aggregation. Proc. Soc. Exp. Biol. Med. 135, 100.
10. Herzog, W.R., Atar, D., Gurbel, P.A., Vogel, R.A., Schlossberg, M.L. & Serebruany, V.L. (1993): Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine. Magnes. Res. 6, 349-353.
11. Stevenson, M.M. & Yoder, I.I, (1970): Studies on platelet aggregation, plasma adenosine diphosphate breakdown and blood coagulation in magnesium deficient calves and rats. Thromb. Diath. Haemorrh. 23, 299-305.
12. Serebruany, V.L., Herzog, W.R., Edenbaum, L.R., Shustov, A.R. & Gurbel, P.A. (1996): Changes in the haemostatic profile during magnesium deficiency in swine. Magnes. Res. 9, 155-163.
13. Rayssiguier, Y. & Gueux, E. (1986): Magnesium and lipids in cardiovascular disease. J. Amer. Coll. Nutr. 5, 507-513.
14. Rishi, M., Ahmad, A., Makheja, A., Karcher, D. & Bloom, S. (1990): Effects of reduced dietary magnesium on platelet production and function in hamsters. Lab. Invest. 63, 717-721.
15. Chang, C., Varghese, P.J., Downey, J. & Bloom, S. (1985): Magnesium deficiency and myoeardial infarct size in the dog. J. Am. Coll.. Cardiol. 5, 280-289.
16. Renaud, S., Ciavatti, M., Thevenon, C. & Ripoll, J.P. (1983): Protective effects of dietary calcium and magnesium on platelet function and atherosclerosis in rabbits fed saturated fat. Atherosclerosis 47, 187-198.
17. Ravn, H.B., Vissinger, H., Kristensen, S.D. & Husted, S.E. (1996): Magnesium inhibits platelet activity - an in vitro study. Thromb. Haemost. 76, 88-93.
18. Gawaz, M., Ott, I., Reininger, A.J. & Neumann, F-J. (1994): Effects of Magnesium on platelet aggregation and adhesion. Thromb. Haemost. 72, 912-918.
19. Satoh, S., Takahashi, K. & Sakuragawa, N. (1993): Thrombospodin as an agglutinin of platelets. Thromb. Res. 72, 509-517.
20. Matsuno, K., Koyatna, M., Takeda, H., Abe, K., Sakurada, K., Miyazaki, T. & Kobayashi, K. (1993): Cytosolic free magnesium concentration in human platelets. Thromb. Res. 69, 131-137.
21. Peerschke, E.I. (1985): pH and magnesium alter 45-calcium binding to platelets at sites other than glycoproteins I or IIb/IIIa. Proc. Soc. Exper. Biol. Med. 179, 232-239.
22. Zijenah, L.S., Morton, L.F. & Barnes, M.J. (1990): Platelet adhesion to collagen. Factors affecting Mg-dependent and bivalent-cation-independent adhesion. Biochem. J. 268, 481-486.
23. Staatz, W.D., Rajpara, S.M., Wayner, E.A., Carter, W.G. & Santoro, S.A. (1989): The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg ++ - dependent adhesion of platelets to collagen. J. Cell. Biol. 108, 1917-1924.
24. Serebruany, V.L., Solomon, S.R., Herzog, W.R. & Gurbel, P.A. (1997). Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors. Pharm. Res. 36, 17-22.
25. Ravn, H.B., Vissinger, H., Kristensen, S.D., Wennmalm, A., Thygesen, K. & Husted, S.E. (1996): Magnesium inhibits platelet activity - an infusion study in healthy volunteers. Thromb. Haemost. 75, 939-944.
26. Serebruany, V.L., Gurbel, P.A., Shustov, A.R., Dalesandro, M., Gumbs, S.I., Grabletz, L, Bahr, R.D., Ohman, E.M. & Topol, E.J., for the GUSTO-III Investigators. (1998): Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myoeardial infarction. Stroke 29, 235-238.
27. Serebruany, V.L., Bahr, R.D., Shustov, A.R., Carpo, C. & Gurbel, P.A. (1997): Marked heterogeneity of platelet aggregation and surface receptor expression in patients presenting with acute myocardial infarction. Circulation 96, 1-261
28. Gurbel, P.A., Serebruany, V.L., Komjathy, S.F., Collins, M.E., Sane, D.C., Scott, H.J., Schlossberg, M.L. & Herzog, W.R. (1995): Regional and systemic platelet function is altered by myocardlal ischemia-reperfusion. J. Thromb. Thrombolys. 1, 187-194.
29. McCarty, M.F. (1996): Complimentary vascularprotective actions of magnesium and taurine: a rationale for magnesium taurate. Med. Hypoth. 46. 89-100.
30. Serebruany, V.L., Schlossberg, M.L., Edenbaum, L.R., Herzog, W.R. & Gurbel, P.A. (1996): Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. Pharmacology 53, 224-233.
31. James, M.F. & Neil, G. (1995): Effect of magnesium on coagulation as measured by thromboelastography. Brit. J. Anaest. 74, 92-94.
32. Sacha, T. & Scotnicki, A.B. (1997): The effect of magnesium on blood coagulation - state of the art literature review from 1959 to 1995. Przeglad. Lekar. 54, 122-125.
33. Sekiya, F., Yoshida, M., Yamashita, T. & Morita, T. (1996): Localization of the specific binding site for magnesium (II) ions in factor IX. FEBS. Lett. 392, 205-208.
34. Vaziri, N.D., Kennedy, S.C., Kennedy, D. & Gonzales, E. (1992): Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am. J. Med. 93, 651-657.
35. Sherrill, G.B., Meade, J.B., Kalayanamit, T., Monroe, D.M. & Church, F.C. (1988): Calcium enhances factor Xa activity independent of gamma - carboxyglutamic acid residues. Thromb. Res. 52, 53-60.
36. Serebruany, V.L., Herzog, W.R. & Gurbel, P.A. (1996): Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Blood. Coag. Fibrinol. 7, 632-640.
37. Sakamoto, T., Ogawa, H., Yasue, H., Oda, Y., Kitajima, S., Tsumoto, K & Mizokami, H. (1994): Prevention of arterial reocclusion after thrombolysis with activated Protein C. Circulation 90, 427-432.
38. Saldeen, T.G., Saldeen, P., Nichols, W.W., Lawson, D.L., Nicolini, F.A. & Mehta, J.L. (1993): Increased production of thromboxane A2 by coronary arterles after thrombolysis. Am. Heart. J. 125, 277-284
39. Tosaki, A., Viossat, I. & Braquet, P. (1991): Effect of cicletanine on reperfusion induced arrhythmias and its relation to 6-keto PGF1 alpha and thromboxane B2 release. Con. J. Physiol. Pharm. 69, 488-493.
40. Corsi, M., Parise, M., Gaja, G. & Ferrero, M.E. (1993): Possible role of defibrotide in endothelial cell protection. Int. J. Tiss. React. 15, 157-161.
41. Laurant, P., Moussard, C., Albert, D., Henry, J.C. & Berthelot, A. (1992): In vivio and in vitro magnesium effects on aortic prostacyclin generation in DOCA-salt hypertensive rats. Prostagl. Leukotr. Essen. Fatty Acids 47, 183-186.
42. Nadler, J.L., Goodson, S. & Rude, R.K. (1987): Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension 9, 379-383.
43. O'Brein, W.F., Williams, M.C., Benoit, R., Sawai, S.K. & Knuppel, R.A. (1990): The effect of magnesium sulfate infusion on systemic and renal prostacyclin production. Prostaglandins 40, 529-538.
44. Calvin, S., Weinstein, L., Witte, M.H. & Finley, P.R. (1990): Plasma levels of fibronectin and prostacyclin metabolite in peripartum preeclamptic women. Am. J. Perinat. 7, 125-129.
45. Serebruany, V.L., Herzog, W.R. & Gurbel, P.A. (1997): Serial changes of the plasma prostanoids during myocardial ischemia - reperfusion in swine: Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Prostagland. Leukotr. Essen. Fatty Acids 56, 135-142.
46. Cremer, K.F., Peiper, J.A., Joyal, M. & Mehta, J. (1984): Effects of diltiazem, dipyridamole, and their combination on hemostasis. Clin. Pharmacol. Ther. 36: 641-644.
47. Velasco, C.E., Jackson, E.K., Morrow, J.A., Vitola, J.V., Inagmi, T. & Forman, M.B. (1993): Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischemia and reperfusion. Cardiovasc. Res. 27, 121-128.
48. Watanabe, T., Suzuki, N., Shimamoto, N., Fujino, M. & Imada, A. (1991): Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ. Res. 69, 370-377.
49. Kemp, P.A., Gardiner, S.M., Bennetl, T. & Rubin, P.C. (1993): Magnesium sulfate reverses the carotid vasoconstriction caused by endothelin-I, angiotensin II and neuropeptide-Y, but not that caused by NG-nitro-L-arginine methyl ester, in conscious rats. Clin. Sci. 85, 175-181.
50. Torregrosa, G., Perales, A.J., Salom, J.B., Miranda, F.J., Barbera, M.D. & Alborch, E. (1994): Different effects of Mg 2+ on endothelin-1 and 5-hydroxytryptamine-elicited responses in goat cerebrovascular bed. J. Cardiovasc. Pharmacol. 23, 1004-1010.
51. Petersen, O.B., Skajaa, K., Svane, D., Gregersen, H. & Forman, A. (1994): The effects of dihydralazine, labetalol and magnesium sulfate on the isolated, perfused human placental cotyledon. Br. J. Obstet. Gynaecol. 101, 871-878.
52. Serebruany, V.L., Schlossberg, M.L., Edenbaum, L.R., Herzog, W.R. & Gurbel, P.A. (In press): Serial changes of soluble endothelin-1 levels during myocardial ischemia - reperfusion. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Pharmacol. Res.
53. Mosesson, M.W. & Umfleet, R.A. (1970): The coldinsoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold insoluble fraction components. J. Biol. Chem. 245, 5728-5738.
54. Bastida, E., Escolar, G., Ordinas, A. & Sixma, J.J. (1987): Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood. 70, 1437-1442.
55. Zucker, M.B., Mosesson, M.W., Broekman, M.J. & Kaplan, K.L. (1979): Release of platelet fibronectin (cold-insoluble globulin) from alpha granules induced by thrombin or collagen; lack of requirement for plasma fibronectin in ADP-induced platelet aggregation. Blood 54, 8-16.
56. Menard, C., Beaulieu, A.D., Audette, M., Corbeil, J. & Latulippe, L. (1985): Studies on fibronectin in inflammatory us. non-inflammatory polymorphonuclear leukocytes of patients with rheumatoid arthritis. II. Synthesis and release of fibronectin in vitro. Clin. Exper. Immunol. 60, 347-353.
57. Dyck, R.F., Orchard, R.C. & Senger, D.L. (1990): The response of plasma fibronectin to acute myocardial infarction in humans. Clin. Invest. Med. 13, 107-110.
58. Serebruany, V.L., Solomon, S.R., Shustov, A.R., Herzog, W.H. & Gurbel, P.A. (1998): Survival in acute myocardial infarction induced by coronary artery ligation: Prognostic relevance of certain nemos tatic factors during the occlusion phase. J. Thromb. Thrombolys. 5, 29-35.
59. Norton, P.A. & Hynes, R.O. (1993): Characterization of HeLa nuclear factors which interact with a conditionally processed rat fibronectin pre-mRNA. Biochem. Biophys. Res. Commun. 195, 215-221.
60. Wang, L., Asem, E.K. & McLaughlin, G.L. (1994): Calcium enhances Acanthamoeba polyphaga binding to extracellular matrix proteins. Invest. Ophthalmol. Vis. Sei. 35, 2421-2426.
61. Serebruany, V.L. , Solomon, S.R., Herzog, W.R. & Gurbel, P.A. (1998): Plasma fibronectin during myocardial ischemia - reperfusion. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Am. J. Hematol. 57, 309-314.
62. Woods, K.L., Fletcher, S., Roffe, C. & Haider, Y. (1992): Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 339, 1553-1559.
63. Woods, K.L. & Fletcher, S. (1994): Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Liecester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 343, 816-819.
64. ISIS-4 (1995): A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS collaborative group. Lancet 345, 669-685.
65. Antman, E.M. (1995): Magnesium in acute MI. Timing is critical. (Editorial) Circulation 92, 2367-2372.
66. LeLorter, J., Gregoire, G., Benhaddan, A., Lappiere, J. & Derderian, F (1997): Discrepancies between metaanalyses and subsequent large randomized controlled trials. N. Engl. J. Med. 337, 536-542.
67. Borzak, S. & Ridker, P.M. (1995): Discordance between meta-analyses and large-scale randomised, controlled trials. Examples from the management of acute myocardial infarction. Ann. Intern. Med. 123, 873-877.
68. Thogersen, A.M., Johnson, O. & Wester, P.O. (1995): Effect of intravenous magnesium sulphate in suspected acute myocardial infarction on acute arrhythmias and long-term outcome. Intern. J. Cardiol. 49, 143-151.
69. Shechter, M., Hod, H., Chouraqui, P., Kaplinsky, E. & Rabinowitz, B. (1997): Acute myocardial infarction without thrombolytic therapy: beneficial effects of magnesium sulphate. Herz. (Suppl. 1): 73-76.
70. Antman, E.M. (1996): Magnesium in acute myocardial infarction: overview of available evidence. Am. Heart J. 132 (2 Pt 2 Su), 487-495.
71. Gurbel, P.A., Anderson, R.D., MacCord, C.S., Scott, H.J., Serebruany, V.L. & Herzog, W.R. (1994): Accelerated intravenous dosing of recombinant tissue plasminogen activator causes rapid but unstable reperfusion in canine model of acute myocardial infarction. Coron. Artery Dis. 5, 929-936.
72. Christensen, C.W., Rieder, M.A., Silverstein, E.L. & Genchoff, N.E. (1995): Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 92, 26517-2621.
73. Herzog, W.R., Schlossberg, M.L., MacMurdy, K.S., Edenbaum, L.R., Gerber, M.J., Vogel, R.A. & Serebruany, V.L. (1995): Timing of magnesium therapy affects experimental infarct size. Circulation 92, 2622-2626.
74. Serebruany, V.L., Schlossberg, M.L., Edenbaum, L.R., Herzog, W.R. & Gurbel, P.A. (1996): Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. J. Cardiovasc. Pharm. 28, 817-823
75. Redwood, S.R., Bashir, Y., Huang, J., Leatham, E.W., Kaski, J.C. & Camm, A.J. (1997): Effect of magnesium sulphate in patients with unstable angina: a double blind, randomized, placebo-controlled study. Eur Heart J. 18, 1269-1277.
76. Durlach, J. (1992): New trends in international magnesium research. Magnes. Res. 5, 1-4.